Study Finds HIF-2 Kidney Cancer Therapy More Effective

Study Finds HIF-2 Kidney Cancer Therapy More Effective

Authored by DesiMD Doctor on 6 Sep 2016 - 18:16

Kidney-cancer

Researchers have found new drugs to treat kidney cancer, bringing good news for approximately 3% of adult malignancies and 90-95% of kidney neoplasms (abnormal growth of tissue, a tumor, characteristic of cancer) in India.

Researchers at Harold C. Simmons Comprehensive Cancer Center have found that a new class of drugs called HIF-2 inhibitors is more effective and better tolerated than the drug Sunitinib, the standard of care, in treating kidney cancer.

Kidney cancer is characterized by a lack of early warning signs, diverse clinical manifestations, resistance to radiation and chemotherapy.

Research Study: According to a study published in the journal Nature, HIF-2 inhibitor PT2399 controlled cancer in half of the tumors when a pre-clinical trial was conducted in mice transplanted with kidney cancer from over 20 patients. In the study, investigators found that HIF-2 inhibition was able to control metastatic kidney cancer even after 7 lines of prior therapy.

"This is a completely new treatment for kidney cancer. We want to make HIF-2 inhibitors available to patients and are currently carrying out clinical trials," said Dr. James Brugarolas, Director of the Kidney Cancer Program.

Dr. Kevin Courtney, Assistant Professor of Internal Medicine and a coauthor of the current study, reported that HIF-2 inhibitors were safe in even in heavily pretreated patients.

The findings show that HIF-2 is a promising target to combat kidney cancer, said Dr. Brugarolas, senior author and a Scholar in Medical Research at UT Southwestern. "Furthermore, it was also better tolerated. As sometimes happens in patients, mice on sunitinib were sickly and lost weight, whereas mice on the HIF-2 inhibitor gained weight while on the study," he adds.

HIF-2 seems to be significant in other types of cancer, including glioblastomas (brain cancer) and the most common type of lung malignancy, the non-small cell lung cancer.

How  Can Kidney Cancer be Prevented?

"In India, younger people do not go for preventive check-ups, which results in delayed diagnosis”, said Dr. Dr Sham Sunder, head of the nephrology department at Ram Manohar Lohia hospital, New Delhi. "If the disease can be diagnosed early, in stage I and II, the progression can be halted with medicines. Those with a family history of kidney failure, recurrent urinary tract infection, diabetes and hypertension must get themselves tested periodically," he added. 

The National Kidney Foundation (NKF) recommends two simple tests to check for kidney disease - Albuminuria-to-creatinine ratio (ACR) and Glomerular filtration rate (GFR) tests.

If you have risk factors such as diabetes, high blood pressure, or family history of diabetes or kidney failure, you must go for kidney tests once a year to rule out any kidney disease or if you have, it can be attended to immediately and treated.

 

Source: Nature – journal, UT Southwestern Medical CenterStudy Finds HIF-2 Kidney Cancer Therapy More Effective

 

*Disclaimer: This website serves as informational purpose only. The content on the DesiMD website, including text, graphics, images, etc., and other content on the DesiMD are for informational purpose only. The content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Please seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Do not disregard professional medical advice or delay in seeking it because of something you have read on the DesiMD website. In case of a medical emergency, call your physician or the hospital immediately. DesiMD does not recommend or endorse any specific tests, physicians, products, procedures, opinions or other information that may be mentioned on the site. Reliance on any information provided by DesiMD at the invitation of DesiMD, or other visitors to the site is solely at your own risk.